Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-21
2007-08-21
Angell, Jon E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
10684440
ABSTRACT:
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
REFERENCES:
patent: 5721138 (1998-02-01), Lawn
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5866551 (1999-02-01), Benoit et al.
patent: 6008344 (1999-12-01), Bennett et al.
patent: 6080580 (2000-06-01), Baker et al.
patent: 6573050 (2003-06-01), Ben-David et al.
patent: 6613567 (2003-09-01), Bennett et al.
patent: 6809193 (2004-10-01), McKay et al.
patent: 2003/0119766 (2003-06-01), Crooke et al.
patent: 2004/0242516 (2004-12-01), Crooke et al.
patent: WO-96/09392 (1996-03-01), None
patent: WO 99/35241 (1999-07-01), None
patent: WO99/35241 (1999-07-01), None
patent: WO-03/014307 (2003-02-01), None
patent: WO 03/014307 (2003-02-01), None
patent: WO-2005/000201 (2005-01-01), None
Morishita et al., Novel Therapeutic Strategy for Atherosclerosis, 1998, Circulation, vol. 98, pp. 1898-1904.
Frank et al., Adenvirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo, 2001, Gene Therapy, pp. 425-430 (received Oct. 11, 2000).
Opalinski et al., Nucleic-Acid Therapeutics: Basic Principles and Recent Applications, Nature Reviews, Jul. 2002, vol. 1, pp. 503-514.
Branch, A good antisense molecule is hard to find, TIBS, Feb. 1998, pp. 45-50.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, 2000, 18:307-319.
Green et al., Antisense Oligonculeotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, J Am Coll Surg, Jul. 2000, vol. 191, No. 1, pp. 93-105.
Anderson et al., A comparison of selected mRNA and protein abundances in human liver, 1997, Electrophoresis, vol. 18, pp. 533-537.
Green et al., Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, 2000, Antisense Therapy in Human Disease, vol. 191, No. 1, pp. 93-105.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, 2000, Stem Cells, 18, pp. 307-319.
Chiesa et al., Reconstitution of Lipoprotein(a) by Infusion of Human Low Density Lipoprotein into Transgenic Mice Expressing Human Apolipoprotein(a), J. of Biological Chem., Dec. 1992, 267:24369-24374.
Frank et al., The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen, Hum. Genet., Aug. 1988, 79:352-356.
Grainger et al., Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice, Nature, Aug. 1994, 370:460-462.
Hajjar et al., The role of lipprotein(a) in atherogenesis and thrombosis, Annu. Rev. Med., 1996, 47:423-442.
Katan et al., Characteristics of human hypo- and hyperresponders to dietary cholesterol, Am. J. Epidemiol., Mar. 1987, 125:387-399.
Lawn et al., Atherogenesis in transgenic mice expressing human apolipoprotein(a), Nature, Dec. 1992, 360:670-672.
McLean et al., cDNA sequence of human apolipoprotein(a) is homologous to plasminogen, Nature, Nov. 1987, 330:132-137.
Morishita et al., Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression, Circulation, Nov. 1998, 98:1898-1904.
Nowak-Gottl et al., Lipoprotein (a): its role in childhood thromboembolism, Pediatrics, Jun. 1997, 99:E11.
Rainwater et al., Lipoprotein Lp(a): effects of allelic variation at the LPA locus, J. Exp. Zool., Sep.-Oct. 1998, 282:54-61.
Sandkamp et al., Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age, Clin. Chem., Jan. 1990, 36:20-23.
Seed et al., Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia, N. Engl. J. Med., May 1990, 322:1494-1499.
Vessby et al., “Diverging Effects of Cholestyramine on Apolipoprotein B and Lipoprotein Lp (a)”, Atherosclerosis Jul. 1982, 44:61-71.
Fritz et al. Cationic Polystyrene Nonoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides. Journal of Colloid and Interface Science, Nov. 1997, 195:272-288.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998, 23:45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells, 2000, 18:307-319.
Dias et al. Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics, Nov. 2002 54:263-269.
K. Kostner et al. “Lipoprotein (a): Still an enigma?”, Current Opinion in Lipidology, Aug. 2002, 13:391-396.
H. Weintraub, “Antisense RNA and DNA”, Scientific American, Jan. 1990, pp. 40-46.
J. Milligan et al., “Current Concepts in Antisense Drug Design”, J. Medicinal Chemistry, Jul. 1993, 36(14):1923-1927.
S. Frank, et al., “Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo”, Gene Therapy, Mar. 2001, 8(6):425-430.
M. Callow, et al., “Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice”, Proc. Natl. Acad. Sci. USA, Mar. 1994, 91:2130-2134.
A. Chin, “On Preparation and Utilization of Isolated and Purified Oligonucleotides”, Katherine R. Everett Law Library of the University of North Carolina, Mar. 14, 2002.
Deverre et al., “A competitive enzyme hybridization assay for plasma determination of phosphodiester and phosphorothioate antisense oligonucleotides”,Nucleic Acids Res. Sep. 15, 1997 25(18):3584-3589.
Ohmichi et al., “The virtues of self-binding: high sequence specificity for RNA cleavage by self-processed hammerhead ribozymes”,Nucleic Acids Res. Feb. 1, 2000 28(3):776-783.
Prosnyak et al., “Substitution of 2-aminoadenine and 5-methylcytosine for adenine and cytosine in hybridization probes increases the sensitivity of DNA fingerprinting”,GenomicsJun. 1994 21(3):490-494.
Substantive Office Action from U.S. Appl. No. 09/923,515, dated Apr. 6, 2005.
Substantive Office Action from U.S. Appl. No. 09/923,515, dated Nov. 3, 2004.
Substantive Office Action from U.S. Appl. No. 09/923,515, dated Mar. 9, 2004.
Substantive Office Action from U.S. Appl. No. 09/923,515, dated Mar. 19, 2003.
International Search Report from PCT/US2004/014540 dated Jan. 25, 2006.
Agrawal, et al., TIBTECH 1996. 14:376-387.
Braasch, D. A., Biochemistry, Apr. 2002; 41(14): 4503-4510.
Gewirtz et al., Proc. Natl. Acad. Sci. 1996, v 93, pp. 3161-3163.
Tamm, I. et al. The Lancet. Aug. 2001, 358: 489-497.
U.S. Appl. No. 60/475,402 filed on Jun. 2, 2003. Rosanne Crooke.
Office Action dated Sep. 25, 2005 that issued in U.S. Appl. No. 09/923,515 filed on Aug. 7, 2001.
Berg, et al.,Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet, Atherosclerosis 163 (2002) 99-104.
Koschinsky, et al.,Lipoprotein(A):on the cutting egde of Occam's Razor, website, Jun. 2004.
Lawn, et al.,Atherogenesis in transgenic mice expressing human apolipoprotein(a), NATURE vol. 360, Dec. 17, 1992, pp. 670-672.
Crooke Rosanne M.
Graham Mark J.
Angell Jon E.
Bowman Amy H.
Isis Pharmaceuticals , Inc.
Knobbe Martens Olson and Bear LLP
LandOfFree
Modulation of apolipoprotein (a) expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of apolipoprotein (a) expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of apolipoprotein (a) expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895557